FDA Calls July PCAC Meeting on Seven Category 2 Peptides

Today — April 15, 2026 — the U.S. Food and Drug Administration published a notice in the Federal Register convening a meeting of the Pharmacy Compounding Advisory Committee (PCAC) this July to review seven peptides currently on the Category 2 bulk drug substances list.^[1][2] The notice is the first concrete procedural step following HHS Secretary Robert F. Kennedy Jr.'s February 27 announcement that roughly 14 peptides would move from Category 2 back to Category 1.^[3]

The FDA also signaled in the same notice that it would "soon remove" the peptides under review from its restricted list pending the committee's recommendation — a significant shift in posture from the agency that originally placed them there in 2023.

---

What the notice says

The Federal Register notice calls for a July PCAC meeting to evaluate whether seven specific bulk drug substances should be added to the Category 1 list — the list of substances that licensed compounding pharmacies can legally use under Section 503A with a patient-specific prescription, or under Section 503B in FDA-registered outsourcing facilities.^[1][6]

Reporting on the notice identifies BPC-157 explicitly among the seven peptides under review, and industry sources point to TB-500 (Thymosin Beta-4) as another substance on the docket.^[2] The remaining five peptides are expected to be drawn from the set Secretary Kennedy flagged in February, which included Sermorelin, CJC-1295, Ipamorelin, AOD-9604, Thymosin Alpha-1, GHK-Cu, MOTS-c, Selank, KPV, and several others.^[3][4]

The full list of the seven peptides being reviewed in July is expected to be clarified when the FDA releases the committee's briefing materials ahead of the meeting, as is standard PCAC practice.

---

Why the PCAC step matters

The Pharmacy Compounding Advisory Committee is the standing federal advisory committee that reviews nominations for inclusion on (or removal from) the 503A and 503B bulk drug substance lists.^[5] A PCAC meeting follows a well-established pattern:

1. Briefing materials are released publicly ahead of the meeting — typically two to four weeks prior.
2. The committee hears presentations from FDA staff, nominators (parties requesting the substance be added), and the public during an open comment period.
3. The committee votes on specific questions posed by the FDA — usually a yes/no on whether a substance should be placed on Category 1.
4. The vote is advisory. The FDA is not bound by it, but historically follows PCAC recommendations in the majority of cases.
5. FDA then issues a proposed or final rule updating the Category lists, typically via a subsequent Federal Register notice.

For the seven peptides now on the July docket, this means the earliest plausible timeline for a final rule is late 2026, and more realistically early 2027 — assuming the committee recommends reclassification and the FDA moves expeditiously.

The notable exception is the FDA's signal that it intends to "soon remove" the peptides from the Category 2 restrictive list. If that happens via interim enforcement discretion — essentially a public commitment not to take enforcement action against compounders preparing these peptides — access could expand well before a final rule is published.^[2]

---

How this fits the sequence

The April 15 notice is the third discrete step in a regulatory shift that has been building since late 2024:

• September 27, 2024 — FDA removed five peptides (AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, Selank) from 503A Category 2 after their nominations were withdrawn, moving them to an "other" status.
• February 27, 2026 — HHS Secretary Kennedy publicly announced that approximately 14 of the 19 Category 2 peptides would be moved back to Category 1.^[3]
• March–April 2026 — Extensive coverage and lobbying from clinics, telehealth platforms, and patient advocacy groups pressed the FDA for a formal response.^[7]
• April 15, 2026 — FDA issues a Federal Register notice convening a July PCAC meeting on seven peptides, and signals imminent removal from the restricted list.

The progression matters. In February, Kennedy's announcement was a political signal without regulatory machinery behind it. Today's notice places that signal inside the statutory process that governs compounding list changes. That is a meaningful tightening of the timeline — but it is still a process, not an outcome.

---

What critics and supporters are saying

The safety concern. Career FDA staff and a number of outside clinicians have emphasized that most Category 2 peptides lack the randomized controlled trial data the agency normally requires for compounding-list inclusion. Independent laboratory testing of gray-market peptides has found substantial quality failures, including contamination, incorrect potency, and wrong-molecule substitutions.^[8] Critics argue that reclassification should wait until clinical safety data catches up.

The access argument. Compounding pharmacies, clinicians who prescribe peptides, and patient advocates argue that the 2023 Category 2 placement pushed patients toward gray-market and international sources that are less safe than a licensed compounding pharmacy operating under state and federal oversight. Their case is that reclassification is itself a safety measure — creating a regulated supply chain where one does not currently exist.^[7]

Industry response. Compounding pharmacy trade groups have already signaled readiness to begin preparing affected peptides the moment the FDA removes them from Category 2 — including investments in USP Chapter 797 sterile compounding capacity and analytical testing protocols.

---

What this means for you

If you are a patient already working with a prescriber and compounding pharmacy: The July meeting is the next milestone to watch. Ask your prescriber whether their pharmacy is monitoring the PCAC docket and what their plan is for each affected peptide — some pharmacies will begin preparing as soon as FDA removes the substance from the restricted list; others will wait for a final rule.

If you have been considering switching from gray-market sources: The regulatory pathway back to licensed pharmacy access is visibly tightening but not yet complete. A licensed compounding pharmacy remains the safer option today even where availability is limited; gray-market enforcement is continuing in parallel with the reclassification push.

If you are new to peptides: Read the Kennedy reclassification explainer and the FDA Peptide Categories Explained first, and consider waiting until at least the July meeting before making any decisions. A reclassified peptide is not an FDA-approved peptide — the evidence base for most of these compounds remains thin.

What to watch next:

1. Release of PCAC briefing materials (typically two to four weeks before the July meeting) — this will confirm which seven peptides are on the docket and what specific questions the committee is being asked.
2. Any interim FDA action to remove peptides from Category 2 ahead of the meeting, as signaled in the April 15 notice.
3. The PCAC vote itself in July — advisory, but highly predictive of final FDA action.
4. A subsequent Federal Register notice issuing the proposed or final rule updating the Category lists.

---

References

1. [1]

   U.S. Food and Drug Administration. “Notice of Meeting: Pharmacy Compounding Advisory Committee — Review of Category 2 Bulk Drug Substances.” Federal Register. 2026. LinkFederal Register notice

   Notice published April 15, 2026 announcing a July 2026 PCAC meeting to review seven peptides for possible reclassification.

2. [2]

   Associated Press / Washington Times. “FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures.” 2026. LinkNews report

   Reporting on the April 15, 2026 FDA federal notice announcing a July advisory committee meeting on seven peptides.

3. [3]

   U.S. Department of Health and Human Services. “Statement by Secretary Kennedy on Compounding and Patient Access to Peptide Therapies.” HHS.gov Press Release. 2026. LinkGovernment statement
4. [4]

   U.S. Food and Drug Administration. “Bulk Drug Substances That Can Be Used in Compounding Under Section 503A and 503B: Category 2 List.” FDA.gov. 2023. LinkRegulatory document
5. [5]

   U.S. Food and Drug Administration. “Pharmacy Compounding Advisory Committee.” FDA.gov. 2024. LinkRegulatory document

   Standing federal advisory committee that reviews nominated bulk drug substances and provides recommendations on inclusion in the 503A and 503B lists.

6. [6]

   U.S. Food and Drug Administration. “Compounding Laws and Policies: Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.” FDA.gov. 2024. LinkRegulatory guidance
7. [7]

   National Public Radio. “The wellness world is eager for RFK Jr.'s promised move on peptides.” 2026. LinkNews feature
8. [8]

   Janoshik Analytical. “Public peptide testing database — 2024 aggregate results.” 2024. Link

   Independent analytical testing laboratory (Prague). 43% of gray-market peptides failed purity claims; 23% of retatrutide samples contained the wrong molecule.

---

---

Related content

News

Kennedy Peptide Reclassification: What Changed and What It Means

The February 27, 2026 HHS announcement that this April 15 notice builds on.

News

FDA Peptide Categories Explained

How the Category 1, 2, and 3 system works and why reclassification matters.

News

What Are Compounding Pharmacies?

The 503A and 503B framework the PCAC advises on.

Peptide

BPC-157

Among the seven peptides explicitly identified for the July PCAC review.

Peptide

TB-500

Another Category 2 peptide expected to be on the July docket.

---